A Phase 1b Multi-Center, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Anti-Tumor Activity of an Alternative Liquid Formulation of ACY-1215 (Ricolinostat) In Combination With Pomalidomide and Low-Dose Dexamethasone In Patients With Relapsed and Refractory Multiple Myeloma

Trial Profile

A Phase 1b Multi-Center, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Anti-Tumor Activity of an Alternative Liquid Formulation of ACY-1215 (Ricolinostat) In Combination With Pomalidomide and Low-Dose Dexamethasone In Patients With Relapsed and Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Ricolinostat (Primary) ; Dexamethasone; Pomalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Acetylon Pharmaceuticals; Celgene Corporation
  • Most Recent Events

    • 28 Nov 2017 Planned End Date changed from 3 Oct 2017 to 15 Oct 2018.
    • 28 Nov 2017 Planned primary completion date changed from 3 Oct 2017 to 15 Oct 2018.
    • 24 May 2017 Planned primary completion date changed from 1 Jul 2016 to 3 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top